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Abstract 
The aim of this position paper is to provide a brief overview of the current status of cardiovascular 
modelling and of the processes required and some of the challenges to be addressed to see wider 
exploitation in both personal health management and clinical practice. In most branches of 
engineering the concept of the Digital Twin, informed by extensive and continuous monitoring and 
coupled with robust data assimilation and simulation techniques, is gaining traction: the Gartner 
Group listed it as one of the top ten digital trends in 2018. The cardiovascular modelling community 
is starting to develop a much more systematic approach to the combination of physics, mathematics, 
control theory, artificial intelligence, machine learning, computer science and advanced engineering 
methodology, as well as working more closely with the clinical community to better understand and 
exploit physiological measurements, and indeed to develop jointly better measurement protocols 
informed by model-based understanding.  Aspects of developments in physiological modelling, model 
personalisation, model outcome uncertainty, and the clinical decision support based on this, will be 




Cardiovascular models can be categorised by their purpose and by their dimensionality. Patient-
generic models can be used for hypothesis creation, mechanistic understanding, device evaluation or 
educational purposes. Patient-specific models can be diagnostic, in that they can return characteristic, 
quantitative measures that might immediately be interpretable to categorise a physiological or 
pathophysiological state. They can also be predictive: they can forecast how the state will evolve, with 
or without an intervention. In this position paper, we will focus on the current-state-of-the-art and 
the future challenges when using cardiovascular models for personalised medicine. Figure 1 illustrates 
some of the considerations that need to be addressed when specifying and deploying a cardiovascular 
model depending on its purpose. There are several challenges in the integration of modelling into a 
clinical workflow. These include: 
• Identification of direct inputs to models in data captured in the clinical process (contributing 
to model personalisation) 
• Identification of direct outputs from models in data captured in the clinical process 
(contributing to model validation) 
• Personalisation of model input parameters to reproduce model output parameters that are 
clinically observable in test cohort  [optimisation processes] 
• Association of personalised model parameters with wider data in clinical record (e.g. is 
resistance and/or compliance associated with age, or body mass index, or co-morbidities such 
as diabetes?)    [exploitation of machine learning processes for model personalisation and 
model interpretation] 
• Development of a principled approach to representation of the physiological envelope for 
individual patients 
The above issues are specifically with regard to the challenges of model personalisation, but before 
this step there are many considerations at the pre-clinical stage. Issues like the selection of 
appropriate rheological models for blood and generic model and code verification are usually 
addressed before personailsation is attempted. 
History 
Zero-dimensional, or lumped parameter, models divide the system into compartments within which 
the fundamental variables are assumed to be uniformly distributed and vary only with time. The 
governing equations are ordinary differential equations. These models can be used to represent the 
whole cardiovascular system physiology or any portion of it. The physiological parameters of pressure, 
flow and volume can be considered equivalent to voltage, charge and current in electrical analogy 
models. A comprehensive review of the components of models of this type has been published by Shi 
et al [1]. These models are readily extended to include the representation of control mechanisms, 
chemical species concentrations and pharmacokinetics processes. Some of the oldest and most 
comprehensive systems physiology models are those published by Guyton[2]. More recently these 
types of models have been integrated with similar 0D systems biology models including the 
representation of biochemical and electromechanical processes at cellular level. Important early work 
to include control mechanisms, and to illuminate processes like haemorrhage, was published by 
Ursino [3]. A very comprehensive set of cardiovascular physiology models, including cellular and 
cardiac components and including the systems physiology models of Guyton, has been curated and 
made publicly available through the Cell-ML initiative of the ABI in Auckland[4]. This facility includes 
tools for the solution of the ODEs and has been one of the most important initiatives of the last two 
decades in the context of standardisation, documentation, ontological representation, curation and 
portability of cardiovascular systems. There are currently many hundreds of models in the CellML 
repository, with over 50 circulation models ranging from the simplest with fewer than ten elements 
to high hundreds.   
One dimensional models are used to describe vascular components in which distribution of quantities 
along the vessel axis are important, and are essential when wave effects, including transmission and 
reflection characteristics, are important. The vessels are represented by partial differential equations 
in time and one spatial dimension. It has been shown formally by MｷﾉｷジｷJ and Quarteroni, [5] that in 
the limit an assembly of 0D models can approximate a 1D system. A comprehensive review of 1D 
modelling, including the fundamental mathematics and the major published vascular tree models 
(typically numbering of the order of 100 to 500 components), has been published by van de Vosse and 
Stergiopulos [6], complemented by a benchmark study of numerical schemes by Boileau et al [7]. 
Often these models are coupled with 0D representations of the heart (variable elastance or single 
fibre models) to produce closed-loop systems.   
The first three-dimensional models of cardiovascular components were performed in the early 1980s 
when it became possible to solve the governing equations of fluid mechanics on large 3D meshes. 
Most commonly the solution processes were based on finite volume or finite element discretisations 
of the Navier-Stokes equations, using custom-written or commercial CFD code. In the earliest 
applications the 3D domains were often simplified and idealised but over three decades, in parallel 
with the development of increasingly powerful medical imaging, more and more detailed models were 
developed and published. More recently some groups used alternative mathematical representations, 
including for example Lattice Boltzmann formulations [8][9] that might have advantages for some 
domains, but overwhelmingly NS solvers have been dominant in cardiovascular applications.  
In the late 1990s and early 2000s there was increasing recognition that, as captured in the context of 
vessel mechanics by 1D models, the cardiovascular fluid domains are not geometrically frozen but are 
bounded, or separated, by flexible structures. This led to an explosion of 3D fluid-solid interaction 
models, based on a range of mathematical formulations for the coupling between solid and fluid 
domains. Stand-out applications for these methods included cardiac mechanics, with one of the first 
publications by Peskin [10], and heart valve mechanics, described by de Hart [11].  
Apart from the physics involved and the way it is represented (0D, 1D or fully 3D) also material 
properties and especially the constitutive behaviour of blood and cardiovascular tissue is determinant 
for the outcome of the models. For vascular tissues important progress has been made recently [12].  
 
Where Now? 
The Virtual Physiological Human 
A major impetus for computational physiology ┘;ゲ ヮヴﾗ┗ｷSWS H┞ デｴW E┌ヴﾗヮW;ﾐ Cﾗﾏﾏｷゲゲｷﾗﾐげゲ Vｷヴデ┌;ﾉ 
Physiological Human initiative, which saw the investment of over 250Mオ over an eight year period. 
A White Paper, authored by opinion-formers in the community, was published in 2005 [13], and 
this was followed by the publication of the Roadmap to the Virtual Physiological Human [14][15] , 
which was based on widespread consultation with the contribution of over 300 active researchers. 
An overview of the goals of the VPH initiative was published in [16], with an update in 2012 [17].  
In the context of vascular applications, a precursor to the VPH was the @neurIST project [18], which 
featured many of the elements that would become core parts of the community efforts. The focus 
was on diagnosis and treatment of aneurysms in the cerebral circulation, and one of the drivers 
was the increased incidence of detection of such aneurysms from advances in medical imaging. A 
workflow was developed to segment the medical image, to produce a mesh suitable for 3D 
computational fluid dynamics analysis to apply appropriate boundary conditions, based on 
coupling with a circulation model extended to include the neurovasculature, to solve the equations 
and to extract potential diagnostic measures from the 3D solutions [19]. This European initiative 
mirrored in several aspects the work of Cebral and his collaborators [20] in the United States. 
@neurIST also formalised the digital representation of all relevant aspects of the patient data in its 
Clinical Reference Information Model [21], incorporating over 2300 data items and the beginnings 
of an ontology for this application. It also produced a prototype clinical decision support system to 
present information to a clinical end user, integrating model outputs with clinical guidelines. 
Some of the largest and most successful projects in the VPH initiative were focused on cardiac 
mechanics: euHeart [22][23] Health-e-child [24] and VP2HF [25] were notable examples. All of 
these were based on exquisitely detailed medical imaging of the heart, coupled with systems 
physiology models for boundary conditions, and targeted at the primary aims of the VPH; effective 
diagnosis, evaluation of individual prognosis and representation of the likely effects of potential 
interventions.  Schievano et al [26] report an important and novel, first-in-man, valve application, 
and noted that デｴWｷヴ ﾏWデｴﾗSﾗﾉﾗｪｷWゲ けIｴ;ﾉﾉWﾐｪW デｴW Iﾗﾐ┗Wﾐデｷﾗﾐ;ﾉ ゲデWヮ┘ｷゲW ヮ;デｴ┘;┞ ﾗa HWﾐIｴ ;ﾐS 
animal testing prior to human application, and may be safer and more relevant, potentially 
ヴWS┌Iｷﾐｪ デｴW ﾐ┌ﾏHWヴ ﾗa ;ﾐｷﾏ;ﾉ W┝ヮWヴｷﾏWﾐデゲ ﾐWIWゲゲ;ヴ┞ aﾗヴ デWゲデｷﾐｪ ﾐW┘ ﾏWSｷI;ﾉ SW┗ｷIWゲげく 
Model Personalisation     
Zero-dimensional models with personalised parameters might have clinical utility in their own right 
in the context of diagnosis and data interpretation. This was explored in an important series of 
papers by Hann and collaborators [27][28] who described processes for the assimilation of clinical 
measurements, including time-series physiological data, in an optimisation process to personalise 
parameters in relatively simple systems physiology models. Potential diagnostic application in 
heart failure was published by Sughimoto et al [29], who demonstrated the separation of systolic 
and diastolic dysfunction in heart failure based on the personalisation of elastance parameters in 
a simple systems physiology model. 
The VPH initiative exemplified one critical aspect of model personalisation, namely the description 
of the individual anatomy based on medical image data. Despite recognition of the importance of 
the boundary conditions [30], the VPH projects generally had lesser focus on this issue. The projects 
that were funded often included some rudimentary personalisation of the boundary conditions to 
match a few clinical measurements. Sometimes measurements of pressure and/or flow at the 
domain boundaries were integrated explicitly in the 3D models, and sometimes they were used to 
tune parameters in lower dimensional model representations that were coupled at the boundaries. 
One of the most important projects to pioneer the latter process in the VPH initiative was the ARCH 
project in renal dialysis [31に34].  
There is increasing recognition that model personalisation needs to be much more than anatomical 
personalisation, and it was evident that the tuning of integrated 3D/0D models to reproduce 
measured clinical data was a continuous and pervasive theme at the World Congress of 
Biomechanics in Dublin in 2018 [35]. This was presaged by the observation by Irene Vignon-
Clemental, at the International Conference on CFD in Medicine and Biology in Albufeira in 2015  
that け┘W ;ヴW ゲWWｷﾐｪ ; ヴWデ┌ヴﾐ デﾗ ゲｷﾏヮﾉWヴ ﾏﾗSWﾉゲ aﾗヴ IﾉｷﾐｷI;ﾉ ｷﾐデWヴヮヴWデ;デｷﾗﾐげ. Marquis et al [36] have 
published a rigorous examination of the personalisation process as applied to a pulsatile 
cardiovascular model. 
Whether personalised 0D models are used independently or as part of multi-scale models, it is 
often the case, especially in a routine clinical pathway, that physiological measurements that might 
support a model personalisation process are sparse (e.g. [37]). It is generally true that a 
personalisation strategy will be most robust when the number of parameters to be personalised is 
relatively small, perhaps fewer than ten, and even the most parsimonious systems model has many 
more parameters. An important element of a personalisation strategy is the identification of the 
model input parameters to which the target output parameters are most sensitive. In this context 
the target outputs include both those that are measured and used for personalisation (to improve 
the robustness of the personalisation step) and those that are used for diagnostic interpretation. 
In practice sensitivity analysis must be an integral part of a personalisation process. 
A special type of measured data is time-series data, when a parameter is measured at multiple 
time points in the cardiac and/or respiratory cycle. These are often collected in clinical research 
protocols, and are much richer in information than the extrema (e.g. systolic and diastolic pressure) 
that are more usually collected in routine clinical pathways. Time series volume and flow data is 
increasingly available from modern dynamic medical imaging protocols. There has been enormous 
progress on the mathematical and theoretical underpinning of the process of data assimilation of 
rich, time series, clinical data. A very promising approach uses unscented Kalman filtering to 
personalise the parameters in systems physiology models, including in the context of boundary 
conditions for 3D models [38に41]. This can be extremely important in situations in which a 
computational model is used to represent accurately the haemodynamics in the measurement 
state, perhaps to extract additional parameters that are not directly measured. It might also be 
very valuable when the aim is to personalise model parameters for subsequent use in simulations 
of predicted changes under an intervention. 
Recognition of Model Uncertainty 
One of the major advances for the cardiovascular modelling community in the last decade has been 
the formal evaluation of model sensitivity and uncertainty [42に45]. Increasing recognition of the 
importance of this topic, and the transatlantic community effort to address the challenges, was 
underlined at the INI Fickle Heart workshop held in June 2019 at the Newton Institute in Cambridge 
[46]. It has been suggested that け1) ia ┞ﾗ┌ Sﾗﾐげデ ;Iﾆﾐﾗ┘ﾉWSｪW ;ﾐ┞ ┌ﾐIWヴデ;ｷﾐデ┞ ｷﾐ デｴW ﾏﾗSWﾉ 
predictions, why would anyone take you seriously? 2) Model predictions are useless without a 
quantification of their uncertainty け. 
Clinicians are used to dealing with uncertainty in their decision processes, but often model-based 
applications return quantitative parameters based on deterministic simulations with no indication 
of the effects of propagation of uncertainties in the clinical data that underpins the model through 
to the model measurements and predictions. This needs to become an integral part of the 
modelling process, and part of any reported results in a decision support system. 
Acute v Long-Term Outcome 
One of the primary benefits of modelling is its predictive capacity. It is able to predict how a state 
will evolve both with and without an intervention. Generally, although not without challenges 
ｷﾐIﾉ┌Sｷﾐｪ デｴW ヴWヮヴWゲWﾐデ;デｷﾗﾐ ﾗa デｴW HﾗS┞げゲ ｴﾗﾏWﾗゲデ;デｷI ﾏWIｴ;ﾐｷゲﾏゲが デｴW ヮヴWSｷIデｷﾗﾐ ﾗa デｴW ゲｴﾗヴデ-
term response to an intervention is massively easier than prediction of the longer-term response. 
The latter inevitably includes biological remodelling processes that produce profound additional 
layers of complexity. There are many challenges in the representation of biological pathways, and 
it is in this sector of research that we need to do much more to recognise the influence of the 
genotype and the way that it governs many of the responses to physiological states. The patient 
phenotype is a combination of all information that is known about an individual, layering 
physiological characterisation on top of the underlying genotype. Our society is increasingly 
conscious of the benefits of improved lifestyles, and we believe that modelling can play a critical 
role in understanding the evolution of the phenotype under all types of intervention. Phenotypic 
plasticity is often measured in large-scale trials, for example of the benefits of exercise, including 
at public health levels, but modelling has the capacity to promote understanding of causative 
associations. We are seeing real progress in the representation of the underlying processes of 
remodelling of the vascular wall [45,46], and even some examples in patient geometries [49], but 
there is much to do to integrate more personalised structural and genotypic data into the process. 
Clinical Decision Support 
A review of the challenges of clinical translation of cardiovascular models was published by Huberts 
et al [50]. These included: 
 the identification of the calculations that are of most direct interest to the medical doctor, 
 the identification of the right level of complexity of a model for a particular purpose,  
 the importance of verification and validation, 
 the need to work in a complex legal and regulatory framework.  
The importance of the latter points, as well as the recognition by the regulatory authorities of the 
potential of simulation, is emphasised by the leadership and engagement of the US Food and Drug 
Administration with the ASME V&V40 initiative [51].  An excellent review of many of the relevant 
issues is presented in [52]  
One of the important issues to consider in designing a clinical decision support system is that of 
resource, both in terms of man-time and compute time. There is always a trade-off between level 
of automation and robustness, although of course automation can eliminate intra- and inter-
observer variability. Compute resource is often not the limiting step in the modern world, although 
still the execution time for a full fluid-solid interaction analysis might take many days even on high 
performance computing resource. What is acceptable depends on the clinical scenario. If decisions 
are taken over a period of days or weeks then a remote service might be appropriate, such as that 
commercialised in the context of coronary FFR by HeartFlow (https://www.heartflow.com/) in 
perhaps the most prominent and successful application of model-based predictive clinical decision 
support in the cardiovascular sector. 
If results are required during the course of a single clinical visit or procedure then it is likely that 
the computations might need to be performed locally, perhaps on the clinical workstation. Such 
scenarios are commonplace in the clinical environment, and this makes it a fertile area of 
application for reduced order models. In the last few years there have been tremendous advances 
in the application or reduced-basis models.  A comprehensive introduction to the reduced-basis 
approach is published by Lassila et al. [53]. Other approaches that might fall under the general 
terminology of a reduced order model include lower order (0D or 1D) models, which have 
underpinned systems physiology models for many years, and meta-models, which seek to capture 
the model behaviour in a simpler model that is fitted to data produced by the full moel . Gaussian 
process emulators have also seen an upsurge of interest in the cardiovascular sector in the last five 
years [54] 
Coronary Fractional Flow Reserve as an Exemplar of Personalised Physiological Modelling 
Perhaps the most successful penetration of cardiovascular modelling tools into clinical application 
is in coronary modelling. Coronary fractional flow reserve (FFR) [55] is a measure of the capacity to 
increase flow to an affected area of the myocardium by removing the blockage caused by a 
coronary stenosis. It is based on a very simple ratio of the pressure distal to the diseased segment 
to the proximal pressure. The computation of this parameter exemplifies many of the issues in 
personalised physiological modelling and its translation to clinical application. 
 The importance of FFR is that it does not simply characterise the local anatomy in isolation. It 
is a physiological measure. It has long been known that tighter lesions, characterised by a 
greater percentage blockage of the artery, generally have greater effect on the patient and 
cause more symptoms. However for the same anatomical blockage, some patients see more 
benefit from the treatment of the lesion than others. The reason is that the flow to the 
myocardium is determined not only by the resistance of the artery in which the lesion is 
observed but also by the resistance of all of the distal arterial and microvascular structures 
that it supplies. In the simplest representation, for steady flow, there are two resistances in 
series, and the important question is how significant the first resistance, that of the diseased 
artery, is to the overall resistance. This very simple model leads to the hypothesis that the 
ratio of distal to proximal pressure, under hyperaemic conditions, might be indicative of the 
capacity to restore flow by removal of the resistance in the coronary artery. Measurement of 
the pressure ratio requires passage of a pressure wire through the lesion, a process that is 
invasive and not completely without risk. If the coronary artery can be segmented from 
medical image data, and an estimate of the personal myocardial resistance can be made, then 
FFR can be computed. This requires the coupling of a local three-dimensional model (or, 
indeed, a one dimensional model [56][57]) of personal coronary anatomy coupled to a 
personalised model of the distal resistance. Morris et al [58] review the challenges and 
limitations of the computation of FFR, including the question of the estimation of distal 
resistance in an individual. 
 Noninvasive computational estimation of FFR is an example of the diagnostic capacity of a 
model. It produces a measure of the consequence of the disease in the reduction of flow. It is 
also predictive: the same measure is used to estimate the ratio by which the flow might be 
improved under an intervention. Because the model describes the system more 
comprehensively than the simple two-resistor model on which the concept is based, it can 
more accurately estimate the capacity for flow improvement. Inevitable there is some residual 
local resistance in the artery after treatment, and this can be simulated in the same way as 
the diseased artery. It is possible to include a very detailed model of the intervention, for 
example the deployment of a stent and the interaction with the wall [59に62], including the 
contact mechanics in the deformable system if this is justified for the application.        
 A major challenge in clinical translation is that very often the model produces measures that 
are hypothesised to be important, but there simply is not the clinical trial basis to prove the 
association between the model measurement and clinical diagnosis or outcome. This was very 
apparent in the @neurIST project outlined earlier. @neurIST produced a series of 
morphometric, structural and haemodynamic characterisations of a cerebral aneurysm that, 
based on our understanding of the physics and biology, ought to be associated with the risk 
of rupture of an individual aneurysm. For example complex, undulating shape, local wall stress 
concentrations and physiologically abnormal wall shear stress might all be indicative of risk. 
@neurIST spent 15Mオ デﾗ SW┗Wﾉﾗヮ ; Iﾗmprehensive computational process to estimate indices 
derived from these parameters, and characterised of the order of 300 aneurysms using these 
tools. However the incidence of rupture is low, and the investment in the computational 
workflow is very small relative to what needs now to be invested to cement the associations 
between these novel indices and clinical sequalae. In contrast, there is a wealth of clinical trial 
data [63][64] that has proven that clinical outcome is improved if a coronary fractional flow 
reserve is used to guide the decision on intervention. This has made computation of FFR a real 
low-hanging fruit for computational physiology. It did not have to be proved that a new 
computational measure had value, only that a computational measure could serve as an 
adequate surrogate for an invasive measure that was already recognised. Several studies have 
reported this association for models derived from CT [65][66] and angiographic [67][68]  
image data.   
 A further challenge in the invasive measurement of FFR is that, at least in its original concept, 
for diagnostic interpretation the pressure measurements should be made when the effect of 
the disease is most apparent に i.e. during hyperaemia (maximal flow). This is induced by 
administration of a drug, also not without potential drawbacks or complications. If the effect 
of the drug can be simulated adequately then this can also be included in the modelling 
process. This also raises the more general issue of simulation of non-rest conditions in all sorts 
of applications. This was recognised by Marsden et al [69] over a decade ago, who proposed 
that respiration and exercise should be incorporated into CFD simulations for realistic 
evaluation of system performance in congenital heart defects [70に72], but outside this 
application there is relatively little literature on the systematic extrapolation of personalised 
models to multiple physiological states. 
EurValve: Applying the Lessons Learned 
The recently-completed EurValve project [73][74] reflects many of the lessons that we have 
learned are important for cardiovascular modelling in clinical decision support. The aim was 
improved clinical decision support for aortic and mitral valve disease. The disease targets were 
aortic stenosis and mitral regurgitation.  In either case the heart works harder to maintain flow. 
The underpinning hypothesis (echoing the philosophy of coronary FFR) was that it is not the local 
anatomical severity of the disease that is important but rather its effect on the overall physiology. 
Left ventricular work and/or peak power might be important diagnostic measures. These 
parameters can be estimated from a personalised systems physiology model. A prediction of the 
reduction in these measures associated with an intervention might represent a clinically-relevant 
quantitative measure of the potential benefit. Furthermore the derived personalised parameters 
might have diagnostic or prognostic capacity in their own right. An overview of the components of 
EurValve, highlighting the integration of a core data and compute infrastructure with 
computational modelling and clinical elements, is illustrated in Figure 2. 
The current diagnostic process was reviewed, cataloguing all of the measurements that are made, 
under what conditions. A series of tables was assembled to list the parameter, or concept, and its 
units. Snapshots are illustrated in Figure 3. This immediately clarified very obvious issues, such as 
the fact that blood pressure might be measured very many times under variable conditions. Other 
measurements, for example volume or flow measures, were often made under very different 
physiological states, and there is a recognised inconsistency between measures made using 
different imaging modalities. A similar table of computational concepts was generated and mapped 
onto the clinical concepts.   
The analysis steps in EurValve exploited many of the methods referenced previously. The most 
parsimonious model that was able to represent the most important clinical concepts, including 
cardiac energetics parameters, was identified and a tuning process was developed to personalise 
the parameters. The primary protocol was based on a characterisation of the valve from 3D 
computational fluid dynamics analysis based on segmented medical image data. The decision was 
taken that the decision support system, including valve and system characterisation, should be 
operable within a single clinical visit. The first operation was segmentation of the valve and local 
portions of the chambers and aorta as appropriate. Then a series of steady state simulations was 
run (with an open, stenotic, aortic valve or a closed, regurgitant, mitral valve) to characterise the 
relationship between pressure drop and flow in the appropriate state for the disease process. This 
characterisation was integrated with the personalised systems model デﾗ けﾏW;ゲ┌ヴWげ デｴW ヮヴWゲゲ┌ヴWが 
volume and flow distribution. The total execution time was of the order of fifteen minutes. 
EurValve also pursued a novel approach that we believe might be the future for integration of 
sophisticated modelling into clinical decision support systems at the point of care. This exploited 
Reduced Order Modelling (ROM) technology from ANSYS, based on a reduced basis re-formulation 
of multiple CFD analysis results. The valve and local geometry was parameterised, so that the full 
3D geometry could be reconstructed from something of the order of ten or twenty parameters. 
The solution space was characterised by performing very many simulations across the parameter 
space and using sophisticated methods to interpolate within this space for any new geometry. With 
this method the primary computational burden is moved off line, and in this case the simulations 
were performed on the Prometheus supercomputer in Cracow in Poland. The resulting ROM was 
installed on a local machine and could return the flow for a given pressure gradient for a new case, 
as part of the simulation process, in less than one second. 
The next step was to decide what simulations to run for an individual. We would argue that the 
most appropriate boundary conditions for a simulation are not necessarily, indeed not likely to be, 
those that are measured in the clinic. Most clinical measurements and images are collected in a 
rest state and/or supine, which might have very little to do with the conditions under which the 
disease is manifest, especially for cardiovascular conditions in which symptoms are usually 
associated with exertion. In the EurValve clinical cohort the individuals were monitored, using the 
Philips Health Watch, over a period of up to two weeks prior to the valve intervention to determine 
their maximum heart rate as they went about their lives. The model was personalised to the clinical 
measurements in the rest state, but a process was developed to extrapolate to the exercise state 
based on published literature for the association between parameters such as LV elastance and 
heart rate. The model prediction included the reductions in these measures under intervention in 
both rest and exercise states. There is primary clinical interest in whether these predictions might 
be reflected in improvement of current outcome measures, such as improvements in the six-
minute walk test. 
The ultimate goal of EurValve was to produce a comprehensive decision support tool, and this 
included further components that are out-of-scope for this article but important in the global 
context. These included presentation of the clinical guidelines interpreted for the individual and a 
module for Case-Based Reasoning so that the user could find similar cases and examine the 
decisions that were taken and the outcomes. The efficient computational supported the routine 
operation of the modelling process, including model personalisation (integrating heart rate data), 
characterisation of rest and exercise states, and prediction of the physiological effect of a candidate 
intervention. Analysis was performed for over 120 individual patients, from three clinical centres. 
Typical 0D model execution time for one case was under five minutes. Detailed reporting of the 
results is out-of-scope for this overview article, but a summary of statistics for personalised 
elastance parameters at rest is presented in Figure 4. It is immediately apparent that there is 
greater variation in the mitral cohort, and that the values for the aortic cohort are closer to the 
normal range. It remains to be seen whether these integrated model-based characterisations are 
diagnostic of the severity of the disease or prognostic of outcome, but it has been proven that they 
can be performed in a relatively routine process in tractable timescales. 
Where next? 
We believe that the fundamental engineering and imaging technology will continue to develop 
apace. The balancing of the timescales of clinical pathways with computational and quality 
assurance requirements when presenting clinical decision support is very problem specific. Where 
the clinical pathway allows there is great merit in a service model in which the clinical team uploads 
data for remote analysis (already relatively routine in clinical service for radiological reporting of 
medical image data and now offered by Heartflow for model-based clinical decision support for a 
coronary application). The potential of reduced-basis ROMs, developed offline using major 
computational resource but implemented on local infrastructure (including potentially on imaging 
hardware in the hospital), has already been introduced, and it can be imagined that a new service 
sector could develop to produce ROMs for all types of clinical applications in the future.  
Many of the attempts to personalise system parameters in cardiovascular models have used 
optimisation or filtering techniques from the engineering community. Most recently there have 
been increased efforts to deploy machine learning techniques from the artificial intelligence 
community. Essentially these seek to learn the model from the data rather than to apply a model 
to compute outputs from inputs. We believe that the integration of these methodologies will 
produce major breakthroughs in model personalisation, perhaps by using a model to reduce the 
machine learning challenge and perhaps by learning model parameters form large clinical datasets. 
This latter function might be particularly useful in situations in which associations exist between 
observations or parameters, but they are not clearly quantified. An example is the influence of co-
morbidities such as diabetes on parameters including microvascular resistance. Although AI and 
hybrid methods can be extremely powerful, and offer huge potential, it is recognised that the けHﾉ;Iﾆ 
Hﾗ┝げ ﾐ;デ┌ヴW poses additional challenges in the context of verification and validation.  
A major deficiency in the whole field of personalised modelling is the capacity to decide on the 
most appropriate set of simulations for an individual, and the capacity to interpret the results. 
When designing an aircraft there is a fundamental process of specification of the flight or service 
envelope. It is known what challenges that aircraft will be subjected to, and the stresses, strains 
and fatigue life are evaluated accordingly. We do not seem to have any similar concept of a 
けヮhysiological envelopeげ デﾗ ヴWヮヴWゲWﾐデ aﾗヴﾏ;ﾉﾉ┞ デｴW W┝I┌ヴゲｷﾗﾐゲ デｴ;デ ;ﾐ ｷﾐSｷ┗ｷS┌;ﾉ ﾏｷｪｴデ ﾏ;ﾆWが ｷﾐ 
what proportions, as they go about their lives. These considerations are included intuitively, and 
sometimes implicitly or explicitly in clinical guidelines, in the clinical decision process but not in any 
formal sense in the modelling process. We believe that the characterisation of this envelope will 
be a significant step forwards in the exploitation of the power of personalised computational 
cardiovascular models. There is much to do to evaluate how different states accumulate to produce 
change, for example the difference between intense exercise interval training and more moderate 
continued exercise, and to develop algorithms to represent the biological processes of remodelling, 
whether negative or positive. These do exist, but they are not mature. For engineering materials 
we have cumulative damage rules that can be applied over a duty cycle [75], but generally there is 
not the data to support physiological system equivalents. 
The concept of the digital twin is already becoming reality in applications such as the continuous 
monitoring, data assimilation and simulation of aircraft engines. We can imagine a future in which 
a personal digital twin continuously assimilates data streamed from wearable devices [76]and 
other pervasive instrumentation to produce characteristic and diagnostic measures and to 
underpin predictive simulations of the effects of all types of interventions, from lifestyle through 
to medical and surgical options. There are special challenges for clinical application with respect to 
the consistency and accuracy of medical data. As discussed previously, often the same parameter 
is measured multiple times and under different protocols: it is recognised that many clinical 
measurements are very dependent on the details of the modality and of the measurement 
protocol, which can be different across clinical centres (with variable degrees of calibration), and 
are often subject to inter- and intra-observer variability. It is not unusual that the modelling 
community produces excellent and predictive results using data from carefully designed research 
trials using state-of-the-art measurement technology, but the benefits do not cascade to clinical 
practice because of the practicalities of routine clinical measurements constrained by economic 
and time considerations. We would suggest for successful model-based clinical decision support it 
is imperative that data accuracy and reproducibility, or data certification [77], is considered when 
developing the processes for interpretation and presentation to clinical end users に and that part 
of this is the propagation of measurement uncertainty through the predictive models. 
The modelling of cardiovascular physiology is just one part of a broader perspective, but it is 
representative in many ways. The community is moving towards a causally cohesive multiscale and 
multiphysics representation of human physiology that will capture what we know at a given time, 
and will continuously evolve as it is confronted by huge amounts of experimental, genotypic and 
phenotypic data. This digital twin will run, eat and age. It will integrate enormous amounts of 
empirical data and physiological insight into a functional and causal whole across scale, space and 
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Figure 4: Statistics for Personalised Elastance Parameters in Left ventricle Model for Aortic Stenosis 
and Mitral Regurgitation Cohorts (120 individuals in total) 
 
[1] Shi Y, Lawford P, Hose R. Review of Zero-D and 1-D Models of Blood Flow in the 
Cardiovascular System. Biomed Eng Online 2011;10. doi:10.1186/1475-925X-10-33. 
[2] Guyton AC, Cowley AW, Coleman TG. Interaction between the Separate Pressure Control 
Systems in Normal Arterial Pressure Regulation and in Hypertension. Hypertens. ね 1972, 
Horizon 2020: Project Number No 689617





What information is used for what purpose?
1972, p. 384に93. doi:10.1007/978-3-642-65343-8_49. 
[3] Ursino M. Interaction between carotid baroregulation and the pulsating heart: a 
mathematical model. Am J Physiol Circ Physiol 2017. doi:10.1152/ajpheart.1998.275.5.h1733. 
[4] Physiome. Physiome Repository n.d. 
https://models.physiomeproject.org/cardiovascular_circulation (accessed August 1, 2019). 
[5] MｷﾉｷジｷJ Vが Q┌;ヴデWヴﾗﾐｷ Aく Aﾐ;lysis of lumped parameter models for blood flow simulations and 
their relation with 1D models. ESAIM Math Model Numer Anal 2004;38:613に32. 
doi:10.1051/m2an:2004036. 
[6] van de Vosse FN, Stergiopulos N. Pulse Wave Propagation in the Arterial Tree. Annu Rev Fluid 
Mech 2011;43:467に99. doi:10.1146/annurev-fluid-122109-160730. 
[7] Boileau E, Nithiarasu P, Blanco PJ, Müller LO, Fossan FE, Hellevik LR, et al. A benchmark study 
of numerical schemes for one-dimensional arterial blood flow modelling[1] Boileau E, 
Nithiarasu P, Blanco PJ, Müller LO, Fossan FE, Hellevik LR, et al. A benchmark study of 
numerical schemes for one-dimensional arterial blood flow modell. Int j Numer Method 
Biomed Eng 2015;31:1に33. doi:10.1002/cnm.2732. 
[8] Hirabayashi M, Ohta M, Rufenacht DA, Chopard B. A lattice Boltzmann study of blood flow in 
stented aneurism. Futur. Gener. Comput. Syst., vol. 20, 2004, p. 925に34. 
doi:10.1016/j.future.2003.12.004. 
[9] Axner L, Hoekstra AG, Jeays A, Lawford P, Hose R, Sloot PMA. Simulations of time harmonic 
blood flow in the Mesenteric artery: comparing finite element and lattice Boltzmann 
methods. Biomed Eng Online 2009;8:23. doi:10.1186/1475-925X-8-23. 
[10] Peskin CS, McQueen DM. A three-dimensional computational method for blood flow in the 
heart I. Immersed elastic fibers in a viscous incompressible fluid. J Comput Phys 1989. 
doi:10.1016/0021-9991(89)90213-1. 
[11] De Hart J, Baaijens FPT, Peters GWM, Schreurs PJG. A computational fluid-structure 
interaction analysis of a fiber-reinforced stentless aortic valve. J Biomech 2003;36:699に712. 
doi:10.1016/S0021-9290(02)00448-7. 
[12] Holzapfel GA, Ogden RW, Sherifova S. On fibre dispersion modelling of soft biological tissues: 
A review. Proc R Soc A Math Phys Eng Sci 2019. doi:10.1098/rspa.2018.0736. 
[13] Ayache N, Boissel J, Brunak S. Towards virtual physiological human: Multilevel modelling and 
ゲｷﾏ┌ﾉ;デｷﾗﾐ ﾗa デｴW ｴ┌ﾏ;ﾐ ;ﾐ;デﾗﾏ┞ ;ﾐS ヮｴ┞ゲｷﾗﾉﾗｪ┞く Vｷヴデ┌;ﾉ Pｴ┞ゲｷﾗﾉ H┌ﾏ ぐ ヲヰヰヶぎヱに29. 
[14] STEPConsortium. Seeding the EuroPhysiome: a roadmap to the virtual physiological human. 
See Http//Www Eur Org/Roadmap 2007:1に105. 
http://scholar.google.com/scholar?hl=en&btnG=Search&q=intitle:Seeding+the+EuroPhysiom
e:+A+Roadmap+to+theVirtual+Physiological+Human#0. 
[15] Fenner JW, Brook B, Clapworthy G, Coveney P V., Feipel V, Gregersen H, et al. The 
EuroPhysiome, STEP and a roadmap for the virtual physiological human. Philos Trans R Soc A 
Math Phys Eng Sci 2008;366:2979に99. doi:10.1098/rsta.2008.0089. 
[16] Hunter P, Coveney P V., De Bono B, Diaz V, Fenner J, Frangi AF, et al. A vision and strategy for 
the virtual physiological human in 2010 and beyond. Philos Trans R Soc A Math Phys Eng Sci 
2010;368:2595に614. doi:10.1098/rsta.2010.0048. 
[17] Hunter P, Chapman T, Coveney P V., de Bono B, Diaz V, Fenner J, et al. A vision and strategy 
for the virtual physiological human: 2012 update. Interface Focus 2013. 
doi:10.1098/rsfs.2013.0004. 
[18] @neurIST. EC FP6 n.d. http://www.aneurist.org (accessed August 1, 2019). 
[19] Villa-Uriol MC, Berti G, Hose DR, Marzo A, Chiarini A, Penrose J, et al. @neurIST complex 
information processing toolchain for the integrated management of cerebral aneurysms. 
Interface Focus 2011;1:308に19. doi:10.1098/rsfs.2010.0033. 
[20] Cebral JR, Castro MA, Appanaboyina S, Putman CM, Millan D, Frangi AF. Efficient pipeline for 
image-based patient-specific analysis of cerebral aneurysm hemodynamics: Technique and 
sensitivity. IEEE Trans Med Imaging 2005;24:457に67. doi:10.1109/TMI.2005.844159. 
[21] Benkner S, Arbona A, Berti G, Chiarini A, Dunlop R, Engelbrecht G, et al. @neurIST: 
Infrastructure for advanced disease management through integration of heterogeneous data, 
computing, and complex processing services. IEEE Trans Inf Technol Biomed 2010;14:1365に
77. doi:10.1109/TITB.2010.2049268. 
[22] EuHeart. EC FP7 project 2012. http://www.euheart.eu (accessed July 30, 2019). 
[23] Smith N, de Vecchi A, McCormick M, Nordsletten D, Camara O, Frangi AF, et al. euHeart: 
Personalized and integrated cardiac care using patient-specific cardiovascular modelling. 
Interface Focus 2011. doi:10.1098/rsfs.2010.0048. 
[24] Health-e-child. EC FP7 n.d. http://www.sim-e-child.org/2/health_e_child_1530471.html 
(accessed August 1, 2019). 
[25] VP2HF. EC FP7 n.d. https://cordis.europa.eu/project/rcn/110725/factsheet/en (accessed 
August 1, 2019). 
[26] Schievano S, Taylor AM, Capelli C, Coats L, Walker F, Lurz P, et al. First-in-man implantation of 
a novel percutaneous valve: A new approach to medical device development. 
EuroIntervention 2010;5:745に50. doi:10.4244/EIJV5I6A122. 
[27] Hann CE, Chase JG, Desaive T, Froissart CB, Revie J, Stevenson D, et al. Unique parameter 
identification for cardiac diagnosis in critical care using minimal data sets. Comput Methods 
Programs Biomed 2010;99:75に87. doi:10.1016/j.cmpb.2010.01.002. 
[28] Hann CE, Revie J, Stevenson D, Heldmann S, Desaive T, Froissart CB, et al. Patient specific 
identification of the cardiac driver function in a cardiovascular system model. Comput 
Methods Programs Biomed 2011;101:201に7. doi:10.1016/j.cmpb.2010.06.005. 
[29] Sughimoto K, Liang F, Takahara Y, Mogi K, Yamazaki K, Takagi S, et al. Assessment of 
cardiovascular function by combining clinical data with a computational model of the 
cardiovascular system. J Thorac Cardiovasc Surg 2013;145:1367に72. 
doi:10.1016/j.jtcvs.2012.07.029. 
[30] Vignon-Clementel IE, Alberto Figueroa C, Jansen KE, Taylor CA. Outflow boundary conditions 
for three-dimensional finite element modeling of blood flow and pressure in arteries. Comput 
Methods Appl Mech Eng 2006. doi:10.1016/j.cma.2005.04.014. 
[31] Bode AS, Huberts W, Bosboom EMH, Kroon W, van der Linden WPM, Planken RN, et al. 
Patient-specific computational modeling of upper extremity arteriovenous fistula creation: Its 
feasibility to support clinical decision-making. PLoS One 2012;7:e34491-. 
doi:10.1371/journal.pone.0034491. 
[32] Merkx MAG, Bode AS, Huberts W, Oliván Bescós J, Tordoir JHM, Breeuwer M, et al. Assisting 
vascular access surgery planning for hemodialysis by using MR, image segmentation 
techniques, and computer simulations. Med Biol Eng Comput 2013;51:879に89. 
doi:10.1007/s11517-013-1060-7. 
[33] Huberts W, Bode AS, Kroon W, Planken RN, Tordoir JHM, van de Vosse FN, et al. A pulse wave 
propagation model to support decision-making in vascular access planning in the clinic. Med 
Eng Phys 2012;34:233に48. doi:10.1016/j.medengphy.2011.07.015. 
[34] Bozzetto M, Rota S, Vigo V, Casucci F, Lomonte C, Morale W, et al. Clinical use of 
computational modeling for surgical planning of arteriovenous fistula for hemodialysis. BMC 
Med Inform Decis Mak 2017;17:26に34. doi:10.1186/s12911-017-0420-x. 
[35] Proceedings. World Congress of Bioengineering. 2018 n.d. http://wcb2018.com/wp-
content/uploads/2018/07/13028-WCB2018-Programme_Web.pdf%0A%0A (accessed August 
1, 2019). 
[36] Marquis AD, Arnold A, Dean-Bernhoft C, Carlson BE, Olufsen MS. Practical identifiability and 
uncertainty quantification of a pulsatile cardiovascular model. Math Biosci 2018. 
doi:10.1016/j.mbs.2018.07.001. 
[37] Bonfanti M, Franzetti G, Maritati G, Homer-Vanniasinkam S, Balabani S, Díaz-Zuccarini V. 
Patient-specific haemodynamic simulations of complex aortic dissections informed by 
commonly available clinical datasets. Med Eng Phys 2019. 
doi:10.1016/j.medengphy.2019.06.012. 
[38] Pant S, Corsini C, Baker C, Hsia TY, Pennati G, Vignon-Clementel IE. Data assimilation and 
modelling of patient-specific single-ventricle physiology with and without valve regurgitation. 
J Biomech 2016. doi:10.1016/j.jbiomech.2015.11.030. 
[39] Pant S, Fabrèges B, Gerbeau JF, Vignon-Clementel IE. A methodological paradigm for patient-
specific multi-scale CFD simulations: From clinical measurements to parameter estimates for 
individual analysis. Int j Numer Method Biomed Eng 2014. doi:10.1002/cnm.2692. 
[40] Wang JX, Hu X, Shadden SC. Data-Augmented Modeling of Intracranial Pressure. Ann Biomed 
Eng 2019;47:714に30. doi:10.1007/s10439-018-02191-z. 
[41] Bertoglio C, Moireau P, Gerbeau JF. Sequential parameter estimation for fluid-structure 
problems: Application to hemodynamics. Int j Numer Method Biomed Eng 2012. 
doi:10.1002/cnm.1476. 
[42] Brynjarsdóttir J, Ohagan A. Learning about physical parameters: The importance of model 
discrepancy. Inverse Probl 2014;30. doi:10.1088/0266-5611/30/11/114007. 
[43] Eck VG, Donders WP, Sturdy J, Feinberg J, Delhaas T, Hellevik LR, et al. A guide to uncertainty 
quantification and sensitivity analysis for cardiovascular applications. Int j Numer Method 
Biomed Eng 2016;32. doi:10.1002/cnm.2755. 
[44] Eck VG, Sturdy J, Hellevik LR. Effects of arterial wall models and measurement uncertainties 
on cardiovascular model predictions. J Biomech 2017;50:188に94. 
doi:10.1016/j.jbiomech.2016.11.042. 
[45] Eck VG, Feinberg J, Langtangen HP, Hellevik LR. Stochastic sensitivity analysis for timing and 
amplitude of pressure waves in the arterial system. Int j Numer Method Biomed Eng 
2015;31:e02711. doi:10.1002/cnm.2711. 
[46] Newton Gateway to Mathematics. Industrial and clinical application of cardiac 
simulations:Quantifying uncertainty in model predictions 2019. 
https://gateway.newton.ac.uk/event/ofbw45/programme (accessed June 4, 2019). 
[47] Ramachandra AB, Humphrey JD, Marsden AL. Gradual loading ameliorates maladaptation in 
computational simulations of vein graft growth and remodelling. J R Soc Interface 2017;14. 
doi:10.1098/rsif.2016.0995. 
[48] Ramachandra AB, Sankaran S, Humphrey JD, Marsden AL. Computational Simulation of the 
Adaptive Capacity of Vein Grafts in Response to Increased Pressure. J Biomech Eng 
2015;137:031009. doi:10.1115/1.4029021. 
[49] Grytsan A, Watton PN, Holzapfel GA. A Thick-Walled FluidにSolid-Growth Model of Abdominal 
Aortic Aneurysm Evolution: Application to a Patient-Specific Geometry. J Biomech Eng 
2015;137:031008. doi:10.1115/1.4029279. 
[50] Huberts W, Heinen SGH, Zonnebeld N, van den Heuvel DAF, de Vries JPPM, Tordoir JHM, et 
al. What is needed to make cardiovascular models suitable for clinical decision support? A 
viewpoint paper. J Comput Sci 2018;24:68に84. doi:10.1016/j.jocs.2017.07.006. 
[51] Morrison, T; Angelone, L; Myers, M; Soneson, J; Wang, Q; Weaver JP. FDA Seminar on V&V 
for Computational Modeling of Medical Devices. figshare. Presentation. n.d. 
https://doi.org/10.6084/m9.figshare.5018783.v3 (accessed August 1, 2019). 
[52] Steinman DA, Migliavacca F. Editorial: Special Issue on Verification, Validation, and 
Uncertainty Quantification of Cardiovascular Models: Towards Effective VVUQ for Translating 
Cardiovascular Modelling to Clinical Utility. Cardiovasc Eng Technol 2018. 
doi:10.1007/s13239-018-00393-z. 
[53] Lassila T, Manzoni A, Quarteroni A, Rozza G. Model Order Reduction in Fluid Dynamics: 
Challenges and Perspectives. Reduc. Order Methods Model. Comput. Reduct., 2014, p. 235に
73. doi:10.1007/978-3-319-02090-7_9. 
[54] Melis A, Moura F, Larrabide I, Janot K, Clayton RH, Narata AP, et al. Improved biomechanical 
metrics of cerebral vasospasm identified via sensitivity analysis of a 1D cerebral circulation 
model. J Biomech 2019. doi:10.1016/j.jbiomech.2019.04.019. 
[55] Pijls NHJ, De Bruyne B. Coronary pressure measurement and fractional flow reserve. Heart 
1998;80:539に42. doi:10.1136/hrt.80.6.539. 
[56] Fossan FE, Sturdy J, Müller LO, Strand A, Bråten AT, Jørgensen A, et al. Uncertainty 
Quantification and Sensitivity Analysis for Computational FFR Estimation in Stable Coronary 
Artery Disease. Cardiovasc Eng Technol 2018;9:597に622. doi:10.1007/s13239-018-00388-w. 
[57] Müller, L. O.; Fossan, F. E.; Strand, A.; Braten, A. T.; Jorgensen, A.; Wiseth, R.; Hellevik LR. 
Impact of baseline coronary flow and its distribution on Fractional Flow Reserve prediction. 
Int j Numer Method Biomed Eng n.d. 
[58] Morris PD, Van De Vosse FNが L;┘aﾗヴS P Vくが HﾗゲW D‘が G┌ﾐﾐ JPく さ┗ｷヴデ┌;ﾉざ ふCﾗﾏヮ┌デWSぶ Fヴ;Iデｷﾗﾐ;ﾉ 
Flow Reserve Current Challenges and Limitations. JACC Cardiovasc Interv 2015;8:1009に17. 
doi:10.1016/j.jcin.2015.04.006. 
[59] Migliavacca F, Petrini L, Massarotti P, Schievano S, Auricchio F, Dubini G. Stainless and shape 
memory alloy coronary stents: a computational study on the interaction with the vascular 
wall. Biomech Model Mechanobiol 2004;2:205に17. doi:10.1007/s10237-004-0039-6. 
[60] Gijsen FJH, Migliavacca F, Schievano S, Socci L, Petrini L, Thury A, et al. Simulation of stent 
deployment in a realistic human coronary artery. Biomed Eng Online 2008;7. 
doi:10.1186/1475-925X-7-23. 
[61] Chiastra C, Migliavacca F, Martínez MÁ, Malvè M. On the necessity of modelling fluid-
structure interaction for stented coronary arteries. J Mech Behav Biomed Mater 
2014;34:217に30. doi:10.1016/j.jmbbm.2014.02.009. 
[62] Migliori S, Chiastra C, Bologna M, Montin E, Dubini G, Aurigemma C, et al. A framework for 
computational fluid dynamic analyses of patient-specific stented coronary arteries from 
optical coherence tomography images. Med Eng Phys 2017;47:105に16. 
doi:10.1016/j.medengphy.2017.06.027. 
[63] Tonino PA, De Bruyne B, Pijls NH  et al. Fractional flow reserve versus angiography for guiding 
percutaneous coronary intervention. N Engl J Med 2009;360:213に24. 
[64] De Bruyne B, Pijls NHJ, Kalesan B, Barbato E, Tonino PAL, Piroth Z, et al. Fractional Flow 
ReserveにGuided PCI versus Medical Therapy in Stable Coronary Disease. N Engl J Med 
2012;367:991に1001. doi:10.1056/nejmoa1205361. 
[65] Koo BK, Erglis A, Doh JH, Daniels D V., Jegere S, Kim HS, et al. Diagnosis of ischemia-causing 
coronary stenoses by noninvasive fractional flow reserve computed from coronary computed 
tomographic angiograms: Results from the prospective multicenter DISCOVER-FLOW 
(Diagnosis of Ischemia-Causing Stenoses Obtained Via Noni. J Am Coll Cardiol 2011;58:1989に
97. doi:10.1016/j.jacc.2011.06.066. 
[66] Nørgaard BL, Leipsic J, Gaur S, Seneviratne S, Ko BS, Ito H, et al. Diagnostic performance of 
noninvasive fractional flow reserve derived from coronary computed tomography 
angiography in suspected coronary artery disease: The NXT trial (Analysis of Coronary Blood 
Flow Using CT Angiography: Next Steps). J Am Coll Cardiol 2014;63:1145に55. 
doi:10.1016/j.jacc.2013.11.043. 
[67] Morris PD, Ryan D, Morton AC, Lycett R, Lawford P V., Hose DR, et al. Virtual fractional flow 
reserve from coronary angiography: Modeling the significance of coronary lesions. Results 
from the VIRTU-1 (VIRTUal fractional flow reserve from coronary angiography) study. JACC 
Cardiovasc Interv 2013;6:149に57. doi:10.1016/j.jcin.2012.08.024. 
[68] Fearon WF, Achenbach S, Engstrom T, Assali A, Shlofmitz R, Jeremias A, et al. Accuracy of 
Fractional Flow Reserve Derived From Coronary Angiography. Circulation 2019;139:477に84. 
doi:10.1161/circulationaha.118.037350. 
[69] Marsden AL, Vignon-Clementel IE, Chan FP, Feinstein JA, Taylor CA. Effects of exercise and 
respiration on hemodynamic efficiency in CFD simulations of the total cavopulmonary 
connection. Ann Biomed Eng 2007;35:250に63. doi:10.1007/s10439-006-9224-3. 
[70] Kung E, Baretta A, Baker C, Arbia G, Biglino G, Corsini C, et al. Predictive modeling of the 
virtual Hemi-Fontan operation for second stage single ventricle palliation: Two patient-
specific cases. J Biomech 2013;46:423に9. doi:10.1016/j.jbiomech.2012.10.023. 
[71] Kung E, Perry JC, Davis C, Migliavacca F, Pennati G, Giardini A, et al. Computational Modeling 
of Pathophysiologic Responses to Exercise in Fontan Patients. Ann Biomed Eng 
2015;43:1335に47. doi:10.1007/s10439-014-1131-4. 
[72] Cutrì E, Meoli A, Dubini G, Migliavacca F, Hsia TY, Pennati G. Patient-specific biomechanical 
model of hypoplastic left heart to predict post-operative cardio-circulatory behaviour. Med 
Eng Phys 2017;47:85に92. doi:10.1016/j.medengphy.2017.06.024. 
[73] EurValve. EC Horizon 2020 n.d. http://www.eurvalve.eu/. 
[74] EurValve video. EC Horizon 2020 n.d. https://www.youtube.com/watch?v=ObCS-Y_HrZw. 
[75] Wikipedia. Fatigue (material) n.d. https://en.wikipedia.org/wiki/Fatigue_%28material%29 
(accessed August 1, 2019). 
[76] King RC, Villeneuve E, White RJ, Sherratt RS, Holderbaum W, Harwin WS. Application of data 
fusion techniques and technologies for wearable health monitoring. Med Eng Phys 
2017;42:1に12. doi:10.1016/j.medengphy.2016.12.011. 
[77] F.v.d.Vosse, H. Hofstraat, S. Omholt, D.K. Iakovidis, E. Nagel, A. Capporozzo, A. Hernandez, C. 
Pichardo PH. Generation of data for model construction, validation and application. 
Discipulus Digit Patient Road Map 2013. https://www.vph-institute.org/upload/discipulus-
digital-patient-research-roadmap_5270f44c03856.pdf (accessed August 1, 2019). 
[78] EurValve. Deliverable 4.1 n.d. http://www.eurvalve.eu/index.php/deliverables/ (accessed 
August 1, 2019). 
 
